On September 30, 2004 Merck & Co., Inc. announced that they would voluntary withdrawal Vioxx from the market worldwide. "Vioxx is a COX-2 selective non steroidal anti-inflammatory drug (NSAID). It is a prescription medication used to relieve signs and symptoms of arthritis and acute pain, which is only to be used by adult patients." (REF) The FDA did not require Merck to withdraw its product from the market however; it was an independent decision on Merck's part. (Hopkins) The FDA does share the same safety concerns for patients taking Vioxx and especially for those that take the drug regularly. After Merck pulled the drug off the market, the FDA issued a public health advisory concerning the use of Vioxx.
An argument can be made that this is indeed Merck's fault. Vioxx made it onto the market with a 17-15-majority vote. Even though Vioxx made its way to the market much controversy swirled around its introduction to the public. Ten of the thirty-two experts on the FDA COX-2 advisory panel that evaluated these drugs had what the Center for Science in Public Interest considered "affiliations" with the drug companies. (Adams) These experts that were considered "affiliates" did receive consulting fees, research support and speaker's fees.
Throughout my extensive research I was not able to find any information that linked any of these "experts" to Merck's more than anyone else. Why should this be a concern now? The only answer to that is because of lawsuits and money. In accounting companies... [continues]
Cite This Essay
(2005, 09). Merck. StudyMode.com. Retrieved 09, 2005, from http://www.studymode.com/essays/Merck-65710.html
"Merck" StudyMode.com. 09 2005. 09 2005 <http://www.studymode.com/essays/Merck-65710.html>.
"Merck." StudyMode.com. 09, 2005. Accessed 09, 2005. http://www.studymode.com/essays/Merck-65710.html.